ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Celastrol, a TFEB (transcription factor EB) agonist, is a promising drug candidate for Alzheimer disease

Zhang, Wei; Wang, Jigang*; Yang, Chuanbin*南方医科大学; 1
Autophagy2022-7-3DOI: 10.1080/15548627.2022.2046437
19被引7阅读
引用收藏
分享

摘要

Alzheimer disease (AD) is the most common neurodegenerative disease. Unfortunately, current effective therapeutics for AD are limited and thus the discovery of novel anti-AD agents is urgently needed. A key pathological hallmark of AD is the accumulation of phosphorylated MAPT/tau (microtubule associated protein tau) aggregates to form neurofibrillary tangles. Autophagy is a conserved catabolic process that degrades protein aggregates or organelles via lysosomes. TFEB (transcription factor EB), a master regulator of autophagy, transcriptionally regulates multiple autophagy, and lysosomal-related genes. A compromised autophagy-lysosomal pathway (ALP) has been implicated in AD progression, and enhancing TFEB-mediated ALP to degrade MAPT/tau aggregates is a promising anti-AD strategy. In a recent study, we showed that celastrol, a natural small molecule with an anti-obesity effect, is a novel TFEB activator, which enhances autophagy and lysosomal biogenesis both in vitro and in animal brains. Consequently, celastrol promotes the degradation of phosphorylated MAPT/tau aggregates both in cells and in the brain of P301S MAPT/tau and 3XTg mice, two commonly used AD animal models. Interestingly, celastrol also alleviates memory deficits in these mice. Altogether, celastrol enhances TFEB-mediated autophagy and lysosomal biogenesis to ameliorate MAPT/tau pathology, suggesting that celastrol represents a novel anti-AD and other tauopathies drug candidate.

学科与关键词

关键词
Alzheimer diseaseautophagycelastrollysosomeMTORtauTFEB
相关
加载中…
  • Impairment of the autophagy-lysosomal pathway in Alzheimer's diseases: Pathogenic mechanisms and therapeutic potential
    Zhang, Wei; Xu, Chengchao; Sun, Jichao; Shen, Han-Ming*; Wang, Jigang*; Yang, Chuanbin*Acta Pharmaceutica Sinica B, 2022, 12(3): 1019-1040.被引 49
  • Clemastine attenuates AD-like pathology in an AD model mouse via enhancing mTOR-mediated autophagy
    Li, Zhen-Yu; Chen, Li-Hua; Zhao, Xiu-Yun; Chen, Hong; Sun, Yan-Yun; Lu, Mei-Hong; Wang, Zhao-Tao; Chen, Mei; Lu, Li; Huang, Wenhui; Chen, Rui; Xu, De-En*; Xu, Ru-Xiang*; Ma, Quan-Hong*Experimental Neurology, 2021, 342: 113742.被引 17
  • TNEA therapy promotes the autophagic degradation of NLRP3 inflammasome in a transgenic mouse model of Alzheimer's disease via TFEB/TFE3 activation
    Lin, Wenjia; Li, Zhao; Liang, Guangfeng; Zhou, Runjin; Zheng, Xiaoyan; Tao, Rongrong; Huo, Qingwei; Su, Chengfu; Li, Min; Xu, Nenggui*; Tang, Chunzhi*; Song, Ju-Xian*Journal of Neuroinflammation, 2023, 20(1): 21.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Autophagy
发表日期
2022-07-03
卷期
第 18 卷, 第 7 期
页码
1740-1742
DOI
10.1080/15548627.2022.2046437
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82003721]; Shenzhen Science and Technology Innovation Commission [JCYJ20210324114014039, JCYJ20210324115800001]; China Postdoctoral Science Foundation [2020M683182]; Guangdong Basic and Applied Basic Research Foundation [2020A1515110549]; National Key Research and Development Program of China [2020YFA0908000]; Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine [ZYYCXTD-C-202002]

作者

  • Z

    Zhang, Wei (第一作者)

    1 · 2

  • W

    Wang, Jigang (通讯)

    2 · southern med univ · 1

查看全部 3 位作者收起作者
  • Y

    Yang, Chuanbin (通讯)

    2 · 1

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417